Aberrant activation of the Wnt/β-catenin pathway in HCC can be accounted for by mutations in the CTNNB1 gene as well as by altered expression of ligands, receptors and inhibitors of the Wnt pathway [26], [27]. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.